US-based technological manufacturer Flex has formed a partnership to deploy its new digital health offering ‘BrightInsight’ on the Google Cloud Platform.
The new secure, managed services solution is designed to aggregate data and provides real-time insights for the optimised value of connected drug, device or combination products.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
At present, firms are focusing on enhancing patient care and drug therapy delivery and management by using the feedback loop created from huge volumes of data collected by various medical devices.
According to Flex, aggregation and analysis of data from several apps and individual devices are necessary to obtain actionable insights required to make an impact.
BrightInsight is designed to aid patients, healthcare professionals, as well as manufacturers through a better understanding of using medical devices, medication adherence, and optimal product development and certification process.
Flex Digital Health senior vice-president Kal Patel said: “We saw the need for a secure cloud platform designed to support highly regulated connected drug delivery and medical devices, going beyond simple connectivity to deliver real-time intelligence and actionable insights.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“With our 20 years of experience operating in global regulated medical environments, and having deployed more than 75 regulated hardware and software medical products, Flex can combine our cross-industry capabilities to simplify our customers’ digital transformation.”
The partnership is intended to allow BrightInsight to use Google Cloud for secure storing, analysis of health information, and to provide insights via customisable analytics dashboards backed by the platform’s machine learning and artificial intelligence (AI) capabilities.
The solution is expected to support control of connected devices, drug dosing, decision making, personalised patient interventions, analysis of trends, and AI-driven insights.
BrightInsight is compatible with CE-Marked and FDA-regulated Class I, II, and III medical devices, combination products and Software as a Medical Device requirements.
It minimises implementation and maintenance costs for several products and allows focus on product submissions by eliminating the need for documentation of the software platform.
